are either sporadic or radiation-induced. Comparable to cases with single meningioma, management of multiple meningiomas mainly consists of surgery and surveillance. Surgery is recommended when a lesion becomes symptomatic or is progressive in size. 3 Clear cell renal cell carcinoma (ccRCC) is the most common and most aggressive subtype of kidney cancer, accounting for around $80% of all cases. The median age at diagnosis is 64 years. If restricted to the kidney, surgery is performed with an average 5-year-survival rate of 92%. However, if the disease spreads locally or systematically, only 12 to 67% of patients survive longer than 5 years. Therapy options for metastatic ccRCC stages are radiochemotherapy and, if applicable, surgery. 4 In hope to improve the devastating survival rates, specific metabolic changes in glucose and lipid pathways of ccRCC might be promising targets for future systemic therapy. 5 Also, tumor-to-meningioma metastasis of ccRCC has been described earlier. 6 The first case of multiple central lesions as tumor-to-meningioma metastasis leading to the diagnosis of a presurgically unknown ccRCC is presented.
Case Presentation

Medical History
In May 2018, a 67 years old patient admitted to the department of neurosurgery with a sudden decrease in vigilance and worsened left hemiparesis. A cranial computed tomography (CT) scan showed multiple intracranial lesions. Her husband reported that she was first diagnosed with multiple meningiomas in 2008 when she suffered from an ischemic stroke that caused a mild residual hemiparesis on the left. Until 2011 she attended regular control appointments to monitor the intracranial tumors. Later, follow-up examinations were evaded.
Clinical Examination
The patient was in a reduced clinical condition (Karnofsky Performance Score 60-70). Sudden weight loss, night sweats, and fever were denied. She presented with GCS 14 (somnolent, but fully oriented) and left-sided hemiparesis. Meningism, nausea, or headache was not apparent. A seizure did not take place and the cranial nerves were deficit-free. Pupils appeared round and symmetrical and reacted to light bilaterally.
The physical examination of the cardiovascular system, lung, and abdomen brought no pathological findings. She took following daily medications: 1 Â 100 mg acetylsalicylic acid, 1 Â 40 mg pantoprazole, 1 Â 10 mg amlodipine, 1 Â 160 mg valsartan, 1 Â 6.25 mg hydrochlorothiazide, and 2 Â 47.5 mg metoprolol.
Radiologic and Laboratory Diagnosis
The cranial magnetic resonance imaging (►Fig. 1) revealed the already known four meningiomas, three within the right brain hemisphere and one on the left side. Two lesions, parietal right and frontal left, presented perifocal edema and a significant progression in size when compared with scans from 2011.
Serum ionogram, hepatic, and renal function analyses were normal. Hematocrit was 0.401, hemoglobin 14.2 g/dL, red blood cell count 5.1 Ã 10^12/L, and platelet count 184 G/L. Leukocytes count was increased up to 16.01 Ã 10^3/µL and Creactive protein slightly upregulated to 9.48 mg/L but no infectious focus could be identified.
Therapy
Already prior to the surgical procedure we began an oral therapy with dexamethasone to control perifocal brain edema. The right parietal meningioma with size progression was identified as a possible cause for the aggravated hemiparesis of the left body side. Therefore, a right frontoparietal osteoplastic craniotomy and microscopic tumor removal under ultrasound guidance was performed.
Histology
Histological examination revealed two distinct tumor morphologies. The first tumor featured meningothelial cells, with some psammoma bodies and whorl-shaped tumor cell growth, without increased mitotic activity. Immunohistochemistry of this tumor was positive for epithelial membrane antigen, somatostatin and vimentin, compatible with meningioma. The second neoplastic process was identified within and adjacent to the meningioma. Histomorphology and immunohistochemical profile strongly suggested a metastasis of a RCC. As typical morphological features, the tumor revealed lobulated growth and tumor cells with clear cytoplasm and distinct borders. The tumor expressed PAX8, CD10, and co-expressed cytokeratins (AE1/3) and vimentin; antigens typically found in renal cell carcinomas. Morphology and immunohistochemistry are summarized in ►Fig. 2.
Clinical Course
A CT staging was performed after the histological diagnosis was received and revealed highly cancer suspect lesions in both kidneys. During the following 16 days the patient recovered from the procedure and was sent to rehabilitation.
Three weeks after release, she was again admitted to our department due to a recurrent decrease in vigilance. Our interdisciplinary tumor board recommended the removal of the second size-progressive lesion, located on the frontal left side. This lesion, too, was diagnosed as tumor-to-tumor metastasis (TTM) of the ccRCC. Again, the patient recovered and could be released after 22 days. During a control appointment at our outpatient center 6 weeks later, she presented with a generally improved clinical condition and radiation therapy was initiated.
Discussion
TTM is a well-known but rare phenomenon in oncology. Campbell et al were the first to define commonly accepted criteria to differentiate TTM from "collision tumors." 7 Although collision tumors occur as two adjacently growing neoplasms of different origin that consecutively happen to infiltrate each other, TTM is defined by (1) exclusion of lymphatic metastasis into lymphoma, (2) the histological proof of two distinct neoplasms, and (3) the enclosure of one tumor by at least a small rim of the other. RCC is considered to be the most common malignant recipient for this type of metastasis formation 8 meningioma is the most common benign entity to be infiltrated by other neoplasms. 9 Breast and lung cancer are known to be the most common donor malignancies for tumor-to-meningioma metastases, [9] [10] [11] [12] [13] but many others were also reported before. 9 To our knowledge, we here describe the first case where extirpation and histological analysis of multiple size-progressive meningiomas revealed metastases of previously undiagnosed ccRCC.
Theories about the origin of TTM were created since the first case of a tumor-to-meningioma case was reported in 1930. 14 To allow cancer cells within the bloodstream or lymphatic fluid to infiltrate tissue and grow, the right environment has to be created. The first to describe this interaction between cancer cells and stroma was Paget in 1889, defining the "seed and soil" theory. 15 Today, this special constellation is called the "pre-metastatic niche" and characterized by immunosuppression, inflammation, angiogenesis and vascular permeability, lymphangiogenesis, organotropism, and reprogramming (metabolic, stromal, and epigenetic). 16 Concerning meningioma, it has been demonstrated that tumor size seems to be associated with better blood perfusion 17 and that overexpression of vascular endothelial growth factor in meningioma is associated with higher microvascular density. 18 There is also evidence that macrophages in meningioma might promote inflammation as well as the permeability of brain-blood barrier, hence contributing to possible brain metastasis formation. 19 In conclusion, meningioma seems to represent a favorable premetastatic niche.
Conclusion
Careful histological analysis of two extirpated central lesions led to the final diagnosis of ccRCC, supported by a post-surgical abdominal CT scan. Hence, the patient could be treated accordingly to protocols for kidney cancer. Clinical results and careful analysis of case reports prove that meningioma seems to represent a favorable premetastatic niche. Our report with multiple tumor-to-meningioma metastases by ccRCC in one patient supports this hypothesis.
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